Multiple Sclerosis and Related Disorders

Papers
(The median citation count of Multiple Sclerosis and Related Disorders is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)
ArticleCitations
Test-retest reliability of the Swedish version of the Modified Fatigue Impact Scale in people with mild to moderate multiple sclerosis73
Preliminary race-ethnicity-based analyses of fall risk among people with multiple sclerosis59
Characteristics of Patients with Newly Diagnosed Multiple Sclerosis: A Five-Year Study at Benghazi Medical Center, Benghazi, Libya58
Psychometric measurement properties and reference values of the six-spot step test, the six-minute walk test, the 25-foot walk test, and the 12-item multiple sclerosis walking scale in people with mul58
Real-World Evidence with Five-Year Data (2017-2022) on the Use of Cladribine Tablets in Patients with Multiple Sclerosis in England: an Updated Analysis from the CLARENCE Study48
Markers of Epstein-Barr virus and Human Herpesvirus-6 infection and multiple sclerosis clinical progression46
Influence of Cigarette, and Waterpipe Smoking, Alcohol, and Drug Consumption on the Occurrence of Late-Onset Multiple Sclerosis46
Comparison of SARS-CoV-2 antibody response after two doses of mRNA and inactivated vaccines in multiple sclerosis patients treated with disease-modifying therapies46
EDSS and Infratentorial White Matter Lesion Volume are Considered Predictors of Fatigue Severity in RRMS46
Evaluation of the use of high-efficacy treatments (HETs) in patients with relapsing-remitting multiple sclerosis in Argentina46
A one year follow of patients with multiple sclerosis during COVID-19 pandemic: A cross-sectional study in Qom province, Iran41
Sexual problems in MS: Sex differences and their impact on quality of life41
Evaluation of adherence to treatment in patients with multiple sclerosis from Latin America40
Diagnosing ‘transition’ to secondary progressive multiple sclerosis (SPMS): A step-by-step approach for clinicians39
“It's on the tip of my tongue!” exploring confrontation naming difficulties in patients with multiple sclerosis39
Plasma 24-hydroxycholesterol is associated with narrower common carotid artery and greater flow velocities in relapsing multiple sclerosis39
Leber Hereditary Optic Neuropathy Presenting as Bilateral Visual Loss and White Matter Disease37
Peripheral nerve vulnerability as risk factor for multiple sclerosis: Possible insights from Neurofibromatosis type 2 (NF2)36
The effects of bupropion on sexual dysfunction in female patients with multiple sclerosis: A double-blind randomized clinical trial36
Involvement Peripheral Nerve System in Multiple Sclerosis36
Effects of constraint induced movement therapy in patients with multiple sclerosis: A systematic review35
The Use of Ocrelizumab in Pediatric Multiple Sclerosis Patients in the United Arab Emirates: A Retrospective Study35
Expert Opinion on COVID-19 Vaccination and the Use of Cladribine Tablets34
Risk factors for development of lymphopenia in dimethyl fumarate-treated patients with multiple sclerosis34
The Relationship Between Smoking and Multiple Sclerosis Severity in Saudi Arabia34
Index of cardiac-electrophysiological balance in relapsing–remitting multiple sclerosis patients treated with fingolimod34
Epidemiology of familial multiple sclerosis and its comparison to sporadic form in Markazi Province, Iran34
Clinical and imaging features of patients with late-onset myelin oligodendrocyte glycoprotein antibody-associated disease34
Anti-Spike IgG in multiple sclerosis patients after BNT162b2 vaccine: An exploratory case-control study in Italy33
Trait mindfulness, emotion dysregulation, and depression in individuals with multiple sclerosis33
Characteristics of recurrence risk perception and coping strategies in patients with neuromyelitis optica spectrum disorder: A qualitative study33
Reconciling lesions, relapses and smouldering associated worsening: A unifying model for multiple sclerosis pathogenesis32
Functional electrical stimulation combined with voluntary cycling accentuates VO2 response in people with severe multiple sclerosis: A pilot study32
Cognitive outcomes in late-onset versus adult-onset Multiple Sclerosis31
57. Cognitive Decline and Motor Handicap in Multiple Sclerosis Patients31
Coexistence of epilepsy or seizure and multiple sclerosis; a single center experience31
143. Navigating the Maze of Multiple Sclerosis Disease Modifying Therapies: Insights from Iran's National MS Registry31
Impact of insurance status on MRI phenotypes in MS30
157. Remibrutinib Exposure in Cerebrospinal Fluid: Insights from a Study in Healthy Subjects29
125. Investigating Psychoses in Pediatric-Onset Multiple Sclerosis: A Systematic Review of Case Reports29
S1P receptor modulators in Multiple Sclerosis: Detecting a potential skin cancer safety signal28
Lipid measures are associated with cognitive functioning in multiple sclerosis patients28
Incidence of multiple sclerosis relapses and pseudo-relapses following COVID-19 vaccination27
Siponimod following Alemtuzumab in secondary progressive MS: investigating sequential therapy–A case series27
Symptoms of PTSD and depression in newly diagnosed people with multiple sclerosis during the outbreak Oct.7th war on Gaza: A case-control study from Jordan27
Can neurofilament lightchain as endpoint in Phase 2 derisk clinical disability worsening in Phase 3 in multiple sclerosis?27
Markedly elevated cerebrospinal fluid white blood cell count in multiple sclerosis: How high is too high?27
Feasibility and usability evaluation of a gamified fatigue management mobile application for persons with multiple sclerosis in everyday life26
Self-reported cognitive function mediates the relationship between employment status and cognitive functioning in persons with multiple sclerosis26
A critical evaluation of machine learning approaches for screening depression and anxiety in early multiple sclerosis25
Macular vascular density alteration patterns in paediatric optic neuritis patients with serum MOG antibody positivity detected by optic coherence tomography angiography25
Multiple sclerosis disease-modifying therapy use in the department of veteran affairs and Medicare: A comparative analysis25
Sarcopenia in patients with multiple sclerosis25
Discontinuation of first-line disease-modifying therapy in relapse onset multiple sclerosis25
Reliability of mobile video-oculography in multiple sclerosis patients using an iPad: A prospective validation study24
How Much Is Enough? Determining Minimum Valid Tracking Periods for Reliable Physical Activity Monitoring24
Sexual Dysfunctions and Self-Esteem in Multiple Sclerosis: A Tunisian Study24
Incidence of malignant neoplasms and mortality in people affected by multiple sclerosis in the epoch of disease-modifying treatments: A population-based study on Tuscan residents24
Identification of common susceptibility genes and drug target genes in multiple sclerosis, systemic lupus erythematosus, and rheumatoid arthritis and its value to guide clinical treatment24
The relationship between cognitive impairment, cognitive fatigue, and visual evoked potential latency in people with multiple sclerosis24
Characterizing causal relationships of visceral fat and body shape on multiple sclerosis risk24
The Management of Lower Urinary Tract Symptoms in Multiple Sclerosis: an Umbrella Review24
Glucagon-like peptide-1 agonist safety and efficacy in a multiple sclerosis cohort24
Relationship between cognitive disturbances and sleep disorders in multiple sclerosis is modulated by psychiatric symptoms24
Prognostic factors of tumefactive demyelinating lesions and differential features for multiple sclerosis in etiology23
Predictors of Progression of Multiple Sclerosis in a Sample of Egyptian Patients23
Atherosclerosis and multiple sclerosis: An overview on the prevalence of risk factors23
Perspectives on fatigue management among veterans living with multiple sclerosis23
Cladribine effects on emotional awareness and reasoning: The CLEAR study23
Multiple Sclerosis in Elderly Patients: When We Can Stopped Treatment?23
Prevalence and Clinical Characteristics of Urological Symptoms in Iranian Multiple Sclerosis Patients: Implications for Quality of Life and Management23
Real World Study of Ocrelizumab in Multiple Sclerosis: Kuwait Experience22
Management of patients with active relapsing-remitting or secondary progressive multiple sclerosis: A French real-world study based on claims data linked to a phase IV study22
23. Vanishing Clues: A Systematic Review of Oligoclonal Band Disappearance in Multiple Sclerosis Patients after Treatment22
The role of pregnancy in relapsing-remitting MS prognosis: A five-year study22
134. Impact of Bowel Dysfunction, Urinary Dysfunction, and Fatigue on Quality of Life in Multiple Sclerosis22
70. Real-World Experience of Cladribine Tablets in the Treatment of Multiple Sclerosis: An Omani Cohort from Khoula Hospital22
Effects of submotor-threshold tibial nerve stimulation on plantarflexion torque in healthy adults and people with multiple sclerosis22
Carotid intima media thickness and multiple sclerosis22
Early use of high efficacy therapies in pediatric forms of relapsing-remitting multiple sclerosis: A real-life observational study22
Dysphagia in Relation with Depression, Anxiety, Fatigue, Sleep Quality, and Pain in Multiple Sclerosis22
120. The Pathological Findings of the First Cervical Spine MRI of The Neuromyelitis Optica Spectrum Disorders Patients21
Dynamic disability measures decrease the clinico-radiological gap in people with severely affected multiple sclerosis21
101. Pseudotumor Demyelinating Lesions in Inflammatory Diseases of the Central Nervous System: An Algerian Series21
30. Thalamic Volume Differentiates Multiple Sclerosis from Neuromyelitis Optica Spectrum Disorder21
67. Domain-Specific and Global Cognitive Impairment in Multiple Sclerosis Patients Based on Cambridge Neuropsychological Test Automated Battery21
81. Gender Difference In Egyptian Patients With Multiple Sclerosis21
95. Patterns of Corpus Callosum Lesions in Demyelinating Diseases of the Central Nervous System21
165. Unmet Needs and Treatment of Relapsing-Remitting Multiple Sclerosis in Saudi Arabia: Focus on the Role of Ofatumumab21
Telehealth in Multiple Sclerosis: Fostering Quality of Life21
41. Neuropathic Pain in Multiple Sclerosis21
Central American and Caribbean consensus for the treatment of MS, NMOSD, and MOGAD20
Neurological efficacy and safety of mesenchymal stem cells (MSCs) therapy in people with multiple sclerosis (pwMS): An updated systematic review and meta-analysis20
No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: Real-world evidence from MS PATHS20
Seroconversion after COVID-19 vaccination for multiple sclerosis patients on high efficacy disease modifying medications20
Real-World Use of Cladribine Tablets (Completion Rates and Treatment Persistence) in Patients with Multiple Sclerosis in England: the CLARENCE Study20
Pregnancy and Infant Outcomes in Women Receiving Ocrelizumab for the Treatment of Multiple Sclerosis: Analysis of the Largest Available Outcomes Database20
Cervical lymph node diameter reflects disease progression in multiple sclerosis20
RETRACTED: New relapse of multiple sclerosis and neuromyelitis optica as a potential adverse event of AstraZeneca AZD1222 vaccination for COVID-1920
Effects of photobiomodulation therapy on muscle function in individuals with multiple sclerosis20
Clinical risk stratification: Development and validation of the DAAE score, a tool for estimating patient risk of transition to secondary progressive multiple sclerosis20
Response: Treatment of multiple sclerosis as a single disease based on the body-pathology-environment model20
Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting mul19
Barriers to Engage in Physical Activity in People with Multiple Sclerosis in Jordan19
Efficacy of Virtual Reality Interventions on Mood and Cognition in Patients with Multiple Sclerosis. a Systematic Review19
The Effect of Rituximab on Mood Disorders in Multiple Sclerosis19
Cytokines/chemokines and soluble immune checkpoint molecules in anti-GABAB receptor encephalitis19
Cross-Cultural Adaptation and Psychometric Evaluation of the Physical Activity and Disability Survey - Revised in People with Multiple Sclerosis19
Higher frequency of Human herpesvirus-6 (HHV-6) viral DNA simultaneously with low frequency of Epstein-Barr virus (EBV) viral DNA in a cohort of multiple sclerosis patients from Rio de Janeiro, Brazil19
Adherence to Treatment in Multiple Sclerosis19
Practical issues concerning the use of Magnetic Resonance Imaging in Multiple Sclerosis in Latin America: Discussion from 16 centres on behalf of the Foro Latam EM Study Group19
Influence of physicians’ risk perception on switching treatments between high- efficacy and non–high-efficacy disease‑modifying therapies in multiple sclerosis19
Is BDNF related to spatial-temporal gait parameters in people with multiple sclerosis? An observational study19
Validation of the Self-Assessed Dynamic Gait Index in People with Multiple Sclerosis18
Peripheral neuropathy and MOG-IgG: A clinical and neuropathological retrospective study18
Levamisole-associated multifocal inflammatory encephalopathy: clinical and MRI characteristics, and diagnostic algorithm18
Microstructural alterations in different types of lesions and their perilesional white matter in relapsing-remitting multiple sclerosis based on diffusion kurtosis imaging18
Glial-mediated pathogenesis and intervention strategies in neuromyelitis optica spectrum disorder18
Using MS induced pluripotent stem cells to investigate MS aetiology18
Tixagevimab and Cilgavimab (Evusheld) Boosts Antibody Levels to SARS-Cov-2 in Patients with Multiple Sclerosis on B-Cell Depleters18
Bio-Psycho-Social Model of Multiple Sclerosis (BPSMMS)18
Implementing Shared Decision-Making for Multiple Sclerosis: The MS-SUPPORT Tool18
Factors contributing to falls in people with multiple sclerosis: The exploration of the moderation and mediation effects18
Capacity of fullerenols to modulate neurodegeneration induced by ferroptosis: Focus on multiple sclerosis18
Monkeypox in Multiple Sclerosis patients: Should we be alert?18
Patients experiences when receiving diagnosis of multiple sclerosis: A qualitative systematic review18
Natalizumab treatment of multiple sclerosis — a Danish nationwide study with 13 years of follow-up18
Low intensity interval robot-assisted gait training improves mobility in people with progressive multiple sclerosis: the PROGR-EX randomized controlled trial18
Effects of inspiratory muscle training on balance, trunk control, fear of falling, respiratory function, and quality of life in people with multiple sclerosis: a randomized controlled trial18
Depression, Anxiety and Alexithymia in Tunisian Patients with Multiple Sclerosis18
Effect of immersive virtual reality training on hand-to-mouth task performance in people with Multiple Sclerosis: A quantitative kinematic study17
Clinical and MRI predictors of cognitive decline in patients with relapsing-remitting multiple sclerosis: A 2-year longitudinal study17
Weak grip strength among persons with multiple sclerosis having minimal disability is not related to agility or integrity of the corticospinal tract17
Impact of multiple sclerosis on male sexual and reproductive health17
Aerobic exercise increases irisin serum levels and improves depression and fatigue in patients with relapsing remitting multiple sclerosis: A randomized controlled trial17
Effect of high frequency repetitive transcranial magnetic stimulation (rTMS) on the balance and the white matter integrity in patients with relapsing-remitting multiple sclerosis: A long-term follow-u17
Quantifying the economic burden to patients of relapse events from neuromyelitis optica spectrum disorders: A cross-sectional survey17
Efficacy and safety of ocrelizumab in patients with relapsing multiple sclerosis: Real-world experience of two Swiss multiple sclerosis centers17
Seasonal variation in attacks of neuromyelitis optica spectrum disorders and multiple sclerosis: Evaluation of 794 attacks from a nationwide registry in Argentina17
Cerebrospinal fluid indices as predictors of treatment response in autoimmune encephalitis17
The prevalence and clinical phenotype of dual seropositive neuromyelitis optica spectrum disorders at a national reference center in South Asia17
Association of health behaviour and clinical manifestation in early multiple sclerosis in Germany – Baseline characteristics of the POWER@MS1 randomised controlled trial17
Smartphone monitoring of cognition in people with multiple sclerosis: A systematic review17
Efficacy and safety of ocrelizumab in pediatric multiple sclerosis17
Exclusion of alternative diagnoses: A component of the 2023 MOGAD criteria that belongs at the forefront, not in the background17
Evaluation of functional outcome measures after fampridine treatment in patients with multiple sclerosis - An interventional follow-up study17
Significant retinal microvascular impairments in multiple sclerosis assessed through optical coherence tomography angiography17
Discontinuation of dimethyl fumarate in multiple sclerosis - a nationwide study17
Asymptomatic MRI lesions in pediatric-onset AQP4-IgG positive NMOSD17
Switching from natalizumab to an anti-CD20 monoclonal antibody in relapsing remitting multiple sclerosis: A systematic review17
Significant upregulation of prenyltransferase-related genes in neuromyelitis optica: Diagnostic potential and clinical correlations17
A systematic review and meta-analysis on gene-environment interaction effects on the associations of vitamin D and sun exposure with multiple sclerosis risk17
Traditional first-line treatment failure rates in neuromyelitis optica spectrum disorder patients included in the Argentinean registry (RelevarEM)17
Upper cervical cord atrophy is independent of cervical cord lesion volume in early multiple sclerosis: A two-year longitudinal study17
Assessing disability progression using the WHODAS 2.0 in multiple sclerosis: Investigating clinical and socio-demographic factors in a large longitudinal cohort study (TONiC-MS)16
Assessment of changes in fatigue and cognitive functioning in the absence of progression independent of relapse activity16
Optical coherence tomography and visual evoked potential and its relationship with neurological disability in patients with relapsing-remitting multiple sclerosis16
Effect of siponimod on retinal thickness, a marker of neurodegeneration, in participants with SPMS: Findings from the EXPAND OCT substudy16
Investigating treatment alternatives for fingolimod in patients with multiple sclerosis developed refractory fingolimod-related genital Human Papilloma Virus (HPV) infection16
153. Efficacy and Safety of Tolebrutinib Versus Placebo in Non-Relapsing Secondary Progressive Multiple Sclerosis: Results From the Phase 3 HERCULES Trial16
124. The Prevalence of Iron Overload in Patients with Multiple Sclerosis in National Guard Health Affair Hospital, Riyadh Center from 2015-202116
MS in the UAE: Population Estimates of Anxiety, Depression and Health-Related Quality of Life16
Long term effects of continuous positive airway pressure treatment of obstructive sleep apnea-hypopnea syndrome in multiple sclerosis patients16
Bone loss and fracture in people with multiple sclerosis: A systematic review and meta-analysis16
Seizures in inflammatory demyelinating disorders of the central nervous system16
Serum ocrelizumab concentrations in patients with multiple sclerosis: A cross-sectional study from routine healthcare16
Social network size and mental health outcomes in youth with neuroinflammatory disorders16
Multiple Sclerosis and biological definitions in neurodegenerative diseases16
106. Assessment of Depression and Anxiety in Patients with Multiple Sclerosis in Morocco16
Reduced physical activity in multiple sclerosis: The role of gait parameters, gait variability parameters and self-reported measure of gait16
Prevalence and incidence of multiple sclerosis in the Netherlands16
Coenzyme Q10 supplementation in multiple sclerosis; A systematic review16
Hospitalisations and humoral COVID-19 vaccine response in vaccinated rituximab-treated multiple sclerosis patients16
Serum Neurofilament Light Chain as a Biomarker of Disease Progression in a Sample of Egyptian Multiple Sclerosis Patients16
Altered gene expression of miR-155 in peripheral blood mononuclear cells of Multiple sclerosis patients: Correlation with TH17 frequency, inflammatory cytokine profile and autoimmunity16
Association between clinical characteristics, acute steroid treatment and oligoclonal bands result in multiple sclerosis: A retrospective study16
79. Sustained Treatment Persistence and High Adherence to Cladribine Tablets in Multiple Sclerosis: Results from Patient Support Program in Gulf Countries16
Quality of life, Knowledge and Access to Treatment in Times of Economic crisis in Lebanon15
Clinical Characteristics of Switching Between Disease Modifying Drugs Among a Sample of Egyptian Multiple Sclerosis Patients15
Validity and reliability of the Six-Minute Pegboard Ring Test for assessing functional capacity and upper limb function in persons with multiple sclerosis15
Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosis15
High-efficacy therapy reduces subcortical grey matter volume loss in Japanese patients with relapse-onset multiple sclerosis: A 2-year cohort study15
Psychotherapy and professional psychological support in multiple sclerosis: Uncovering patients’ patterns of access and preferences15
Beyond the B-cell as a treatment target in multiple sclerosis15
Linking X to MS: Immunity and demyelination on the X-chromosome in MS15
COVID-19 in neuromyelitis optica spectrum disorder patients in Poland15
Comparative efficacy and safety of ozanimod and ponesimod for relapsing multiple sclerosis: A matching-adjusted indirect comparison15
Telemedicine and Multiple Sclerosis Management in the Era of COVID-19, Al-Azhar Experience15
The effect of COVID-19 lockdowns on exercise and the role of online exercise in Australians with multiple sclerosis15
Serum Oxidative Stress Biomarkers in Relapsing Remitting Multiple Sclerosis Patients with No Evidence of Disease Activity15
The serum kynurenine pathway metabolic profile is associated with overweight and obesity in multiple sclerosis15
Multiple Sclerosis in Middle East North Africa (MENA) Region: Challenges, Achievements and Opportunities.15
SARS-CoV-2 infection in patients with neuroimmunological disorders in a tertiary referral centre from the north of Portugal15
Effects of Cognitive and Motor Secondary Tasks on Gait Performance in Healthy Controls and Multiple Sclerosis Patients with and Without Fall History15
Emerging trends in multiple sclerosis research15
Transcranial direct current stimulation for spasticity in patients with multiple sclerosis: Exploring novel routes15
Clinical characteristics, sero- prevalence, treatment and outcomes of AQP4 IgG associated neuromyelits optic spectrum disorder (NMOSD) in Sri Lanka15
Effectiveness of acceptance and commitment therapy for improving quality of life and mood in individuals with multiple sclerosis: A systematic review and meta-analysis15
Increased healthcare utilization in the year before multiple sclerosis diagnosis15
Prevalence of Urinary Tract Symptoms in Patients with Multiple Sclerosis and Health Care Seeking Behavior: A Cross Sectional Study in Riyadh, Saudi Arabia.15
Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis15
Hypogonadism in men with multiple sclerosis: Prevalence and clinical associations15
Pregnancy Outcomes in Patients with Multiple Sclerosis Following Exposure to Ofatumumab15
Self-reported fatigue impact is associated with frequency of falls and injurious falls in people with multiple sclerosis14
Unwrapping the “black box” of balance training in people with multiple sclerosis – A descriptive systematic review of intervention components, progression, and intensity14
Are we ready for CD19-targeted CAR T-cell therapies in MS?14
A cross-sectional analysis of persistence to disease-modifying therapies in treatment naïve and experienced patients with relapsing multiple sclerosis at a health-system specialty pharmacy14
The effect of cooling garments to improve physical function in people with multiple sclerosis: A systematic review and meta-analysis14
Comparison of vision-related quality of life in NMOSD and MOGAD14
Serum neurofilament light chain as a biomarker in multiple sclerosis: A cross-sectional observation in real-world clinical practice14
Racial disparities in hypertension management among multiple sclerosis patients14
Aggressive Pediatric Multiple Sclerosis: Features and therapeutic Challenges14
Evaluating the impact of systematic reporting of patient-reported outcome measures on depression and anxiety levels in people with multiple sclerosis: a randomized controlled trial14
Serum neurofilament light chain levels suggest neuroprotection following bexarotene-induced remyelination in people with relapsing remitting multiple sclerosis14
Effects of six-month home-based neuro-functional and resistance training interventions on cognitive and motor performance in multiple sclerosis patients with cognitive impairment: A randomized control14
Clinical features of MOGAD with brainstem involvement in the initial attack versus NMOSD and MS14
Ocrelizumab during pregnancy and lactation: Rationale and design of the MINORE and SOPRANINO studies in women with MS and their infants14
Neural Substrates of Mobility and Postural Impairments in People with Multiple Sclerosis14
Range of motion abnormalities in the lower limb joints during gait in youth with multiple sclerosis14
Navigating the discontinuation of multiple sclerosis first line treatments: A paradigm shift in patient care14
Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes14
Mesenchymal stem cells in clinical trials for multiple sclerosis: A systematic literature review and review of clinical trials14
Additive beneficial effects of aerobic training and royal jelly on hippocampal inflammation and function in experimental autoimmune encephalomyelitis rats14
Aims & Scope & Editorial Board13
Cognitive Impairment in Multiple Sclerosis: the Role of Sleep Disorders13
31. Quantitative susceptibility mapping (QSM)-based regional iron concentration: Does it correlate with brain volume loss? An analysis of 250 regions of interest (ROIs)13
Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosis13
Physical activity is associated with fatigue in persons newly diagnosed with multiple sclerosis13
Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies13
Mitochondrial DNA Copy Number as a Biomarker of Multiple Sclerosis13
Effect of alemtuzumab on fatigue, quality of life, and patient/caregiver-reported outcomes in relapsing-remitting multiple sclerosis—A real-world evidence study13
Short and mid-term research priorities for Veterans with multiple sclerosis: A modified Delphi process engaging Veterans, researchers, and operational partners13
Investigating the impact of different dichotomous definitions for cognitive impairment on functional connectivity in secondary progressive MS13
The Association of ApoE Genotype and Cognitive Impairment in Multiple Sclerosis (MS): A Systematic Review and Meta-Analysis13
44. Breaking Free from the Six-Month Cycle13
The Impact of Bladder Dysfunction on Physical Activity in Multiple Sclerosis Using Wearable Technology13
Patient-reported quality of life and perceived disease burden in mexican patients with neuromyelitis optica spectrum disorder: a cross-sectional analysis13
Allied health professionals knowledge and clinical practice in telehealth exercise behavioural change for multiple sclerosis13
Primary Biliary Cirrhosis-Autoimmune Hepatitis Overlap in Patient with Multiple Sclerosis Treated with Ocrelizumab: A Case Study and Literature Review13
Anti-HBs titers are not decreased after treatment with oral Cladribine in patients with Multiple Sclerosis vaccinated against Hepatitis B virus13
Can we improve outcomes in MS around the world? Access and global considerations across income strata13
Rapid depletion of CD20+ B and T cells following ofatumumab therapy onset13
Optic Nerve Imaging Solving Demyelination Mystery13
148. Correlations Between Cognitive Impairment and Multiple Sclerosis Treatments13
Revolutionizing MS Care and Research: Inside Iran's Nationwide Multiple Sclerosis Registry13
Preferences for neuromyelitis optica spectrum disorder treatments: A conjoint analysis with neurologists in Spain13
Feasibility and tolerability of portable, low-field brain MRI for patients with multiple sclerosis13
The influence of disease-modifying therapy on hidden disability burden in people with newly diagnosed relapsing-remitting multiple sclerosis13
Cross-cultural adaptation, content validity, test-retest reproducibility and reliability of the reintegration to normal living index: Brazilian Portuguese version13
Parenchymal Neuro-Behçet's disease or Comorbid Behçet's disease with multiple sclerosis: A discriminative analysis of a complex clinical entity13
0.18086910247803